Oralmat is manufactured by Schumacher Pharmaceutical Ltd. of Melbourne, Australia. Schumacher’s is a small company headed by two brothers, Monty and David Rudov who have spent fourteen years developing, preserving, storing, stabilizing, purifying, potentizing and refining the extraction process of the young rye plants which they knew contained many important phytonutrients.

In Finland, Professor Herman Aldercreutz observed that there were remarkably LOW INCIDENCES OF BREAST, BOWEL AND PROSTATE CANCER in the Finnish population in different periods of its history. He associated this with periods of high RYE consumption and postulated the existence of phytoestrogens in the RYE plant. He succeeded in finding these, isolated and identified them and has been working with them for the past 30 years. He has shown significant health benefits in the consumption of rye products by a statistically large group of Finnish men and women.

Oralmat began when the makers noted the healing effect that RYE had on animals when they chewed it. Years after that observation, they found a way to extract – "live" – the powerful hormones, protectants and self-curative polysaccharides, phytoestrogen, genistein, matiaresinol, beta 1, 3 glucan, Coenzyme Q10, Squalene, all possessed by RYE as part of its natural biochemical immune complement.

The non-toxic, patented, potentized, harmless and activated extract of Rye, on which it is based, is proving to be a broad spectrum therapeutic agent possessing numerous healing actions that work synergistically. Among them is superior wound healing, anti-inflammatory, immunomodulating, blood profile normalizing, anti-viral, anti-bacterial, anti-fungal, anti-allergy, residual scar tissue minimizing, and powerful analgesic properties.

Soon after Oralmat Drops were released for sale we received reports that it cleared sore throats in ten minutes, coughs, colds and flu in 24 to 48 hours, even if the subject was HIV+.

Then we began receiving reports that Oralmat cleared sinusitis, allergic sneezing and hay fever in minutes. This was followed by reports that it relieved asthma after 3 to 4 weeks, if used as directed daily. Much less in children. Doctors confirmed this.

A Melbourne doctor, who used the drops as a last resort on a patient’s asthma, where all else had failed, found that Oralmat used as directed, cleared his patient’s asthma after 4 weeks. He told a colleague, who was an Associate Professor of Clinical Pharmacology and Preventive Medicine and suggested we call him. This we did and the Associate Professor asked for a submission and product for evaluation. Within 2 weeks of our submission the Associate Professor told us that the papers were the most compelling anecdotal reports he had ever reviewed. They pointed to our products being capable of doing things unknown in modern western medicine.